Core Insights - The medical device sector experienced a 0.8% increase on July 7, with a net capital outflow of 229.15 million [1] - A total of 75 stocks in the sector rose, while 44 stocks declined [1] Sector Performance - The top ten decliners in the sector included: - Rejing Bio (-6.14%) - Gongdong Medical (-4.2%) - Botao Bio (-3.67%) - Mindray Medical (-3.3%) - Ruimai Te (-3.28%) - BGI Genomics (-3.2%) - Xinmai Medical (-2.73%) - Yuyue Medical (-2.66%) - Xiangyu Medical (-2.59%) - Berry Genomics (-2.53%) [1][1] Stock Highlights - Notable stocks with significant movements included: - Baolite: Current price 9.95, up 0.028, with net capital of 842.20 million, accounting for 27.77% - Wuzhou Medical: Current price 38.61, up 19.99, with net capital of 3131.39 million, accounting for 17.35% - Jigaofazhan: Current price 3.36, up 10.16, with net capital of 5097.91 million, accounting for 38.75% [1][1][1]

Company Overview - Company name: Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, production, and sales of disposable medical consumables [1] - Main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - As of Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - Net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The sales gross margin stood at 32.40% [1] Market Position - The company's closing stock price on July 4 was 20.72 yuan, with a PE ratio of 29.68 times [1] - The total market capitalization is 4.569 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 51.05 times, with a median of 36.62 times, placing Gongdong Medical at the 66th position in the industry [1][2] Institutional Holdings - As of Q1 2025, four institutions hold shares in Gongdong Medical, including two funds, with a total holding of 14.5259 million shares valued at 402 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Gongdong Medical, which has a closing price of 19.68 yuan and a rolling PE ratio of 28.19 times, with a total market value of 4.339 billion yuan [1][2] - Gongdong Medical ranks 61st in the medical device industry, which has an average PE ratio of 51.29 times and a median of 37.02 times [1][2] - As of March 31, 2025, Gongdong Medical has 8,909 shareholders, an increase of 735 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Gongdong Medical specializes in the research, production, and sales of disposable medical consumables, with main products including medical testing, blood collection, collection, medical care, and drug packaging [1] - In the latest quarterly report for Q1 2025, Gongdong Medical reported an operating income of 264 million yuan, a year-on-year decrease of 2.74%, and a net profit of 27.41 million yuan, down 39.23% year-on-year, with a gross profit margin of 32.40% [1]

Core Viewpoint - The legal opinion letter issued by Zhejiang Tiance Law Firm confirms that Zhejiang Gongdong Medical Devices Co., Ltd.'s differentiated equity distribution plan for the 2024 profit distribution complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [1][4][7]. Group 1: Differentiated Equity Distribution - The company plans to repurchase shares using self-owned funds through centralized bidding, with the repurchased shares intended for employee stock ownership plans or equity incentives [4]. - As of the date of the legal opinion, the number of shares in the repurchase account is 292,080, accounting for 0.19% of the total share capital of 157,578,415 shares [4]. - The repurchased shares will not participate in the 2024 profit distribution, leading to a need for special handling of the differentiated equity distribution [4][5]. Group 2: Profit Distribution and Repurchase Amount - The company distributed a total cash dividend of 109,813,154.50 yuan for the first half of 2024, with the total cash dividend and repurchase amount combined reaching 145,810,244.10 yuan, which is 84.95% of the net profit attributable to shareholders [5]. - The repurchase amount for the year is 35,997,089.60 yuan, which is considered in the cash dividend calculation [5]. Group 3: Calculation Basis for Differentiated Equity Distribution - The total share capital as of the date of the legal opinion is 157,578,415 shares, with 157,286,335 shares participating in the distribution [6]. - The reference price for ex-rights and ex-dividends is calculated based on the previous closing price and cash dividends, resulting in an actual distribution reference price of 19.1714 yuan per share [6][7]. - The impact of the differentiated equity distribution on the reference price is minimal, with an absolute value of less than 1% [7]. Group 4: Conclusion - The legal opinion concludes that the differentiated equity distribution plan adheres to the Company Law, Securities Law, and relevant regulatory guidelines, ensuring the protection of the interests of the company and its shareholders [7].

Core Points - The company plans to distribute a cash dividend of 0.40 CNY per share and a stock bonus of 0.4 shares for each share held, approved at the 2024 annual general meeting on May 27, 2025 [1][2] - The total cash dividend to be distributed amounts to 62,914,534 CNY, and the total shares after the distribution will be 220,492,949 shares [2][9] - The ex-dividend date is set for June 26, 2025, with the record date being June 25, 2025 [3][4] Dividend Distribution Details - The cash dividend will be distributed based on the total share capital minus the shares held in the company's repurchase account, which do not participate in the profit distribution [2][4] - The reference price for the ex-dividend will be calculated using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio) [2][3] - The company will not withhold income tax on the cash dividend at the time of distribution; instead, it will be calculated based on the holding period of the shares [5][6] Share Capital Structure - Before the distribution, the total number of circulating shares was 157,578,415, which will increase by 62,914,534 shares after the distribution [9] - The diluted earnings per share for the fiscal year 2024, after the stock bonus, is projected to be 0.78 CNY [8]

浙江天册律师事务所 法律意见书 关于 浙江拱东医疗器械股份有限公司 2024 年度差异化权益分派事项的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 1 法律意见书 浙江天册律师事务所 关于浙江拱东医疗器械股份有限公司 2024 年度差异化权益分派事项的 法律意见书 编号：TCYJS2025H0972 号 致：浙江拱东医疗器械股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江拱东医疗器械股份有限 公司（以下简称"拱东医疗"或"公司"）的委托，根据《中华人民共和国证券 法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司 法》"）、《上市公司股份回购规则》《上海证券交易所股票上市规则》及《上海 证券交易所上市公司自律监管指引第 7 号——回购股份》（以下简称"《监管指 引》"）等法律、法规及规范性文件的相关规定，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，就公司 2024 年度利润分配所涉及的差异化权益分派 （以下简称"本次差异化权益分派"）相关事项出具本法律意见书 ...

证券代码：605369 证券简称：拱东医疗 公告编号：2025-023 浙江拱东医疗器械股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 | | | | | 新增无限售 | 现金红利发 | | --- | --- | --- | --- | --- | --- | | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 条件流通股 | 放日 | | | | | | 份上市日 | | | Ａ股 | 2025/6/25 | － | 2025/6/26 | 2025/6/26 | 2025/6/26 | 差异化分红送转： 是 一、通过分配、转增股本方案的股东大会届次和日期 本次利润分配及转增股本方案经公司2025 年 5 月 27 日的2024年年度股东大会 审议通过。 二、分配、转增股本方案 1.发放年度：2024年年 ...

Core Viewpoint - Gongdong Medical (605369.SH) announced the early termination of the share reduction plan by major shareholders and the results of the share reduction [1] Group 1: Share Reduction Details - The company disclosed that Taizhou Jincheng Investment Management Partnership (Limited Partnership) planned to reduce its holdings by up to 1,575,784 shares, representing 1% of the total share capital [1] - The company's general manager, Zhong Weifeng, intended to reduce his holdings by up to 302,158 shares, accounting for 0.19% of the total share capital [1] - As of May 30, 2025, Jincheng Investment had reduced its holdings by 1,575,708 shares, while Zhong Weifeng had reduced 294,936 shares [1] Group 2: Financial Impact of Share Reduction - Zhong Weifeng's share reduction occurred between March 13, 2025, and May 30, 2025, with a total amount of 8,526,906.60 yuan at a price range of 28.08 to 30.98 yuan per share [2] - Jincheng Investment reduced its holdings from March 11, 2025, to May 30, 2025, totaling 43,171,696.32 yuan at a price range of 23.64 to 30.53 yuan per share [2] - The combined total amount from both parties' share reductions was 51,698,602.92 yuan [2] Group 3: Shareholding Structure - Prior to the reductions, Zhong Weifeng held 1,208,634 shares (0.77% of total share capital), while Jincheng Investment held 11,760,000 shares (7.46% of total share capital) [2] - After the reductions, Zhong Weifeng's holdings decreased to 913,698 shares (0.58%), and Jincheng Investment's holdings decreased to 10,184,292 shares (6.46%) [2] - The major shareholders, including Shi Huiyong and Shi Yibei, collectively held 102,688,600 shares, representing 65.17% of the total share capital [2][3]

Key Points - The core point of the article is the trading and shareholder activity of Gongdong Medical, highlighting a decrease in stock price and changes in major shareholders' positions [1][3]. Trading Information Summary - On May 30, 2025, Gongdong Medical's stock closed at 26.27 yuan, down 0.04%, with a turnover rate of 1.11% and a trading volume of 17,500 shares, resulting in a transaction amount of 46.5264 million yuan [1]. - The capital flow on the same day showed a net inflow of 6.0551 million yuan from main funds, while speculative funds experienced a net outflow of 6.2977 million yuan, and retail investors had a net inflow of 242,600 yuan [1][3]. Shareholder Changes Summary - On May 30, 2025, Gongdong Medical announced that shareholder Taizhou Jincheng Investment Management Partnership (Limited Partnership) reduced its holdings by a total of 1.3132 million shares, accounting for 0.8333% of the company's total share capital, during a period when the stock price fell by 9.41% [1]. - The announcement detailed that prior to the reduction, Jincheng Investment held 11,760,000 shares, representing 7.46% of the total share capital, while the company's director and general manager, Zhong Weifeng, held 1,208,634 shares, or 0.77% of the total [1]. - Jincheng Investment's planned reduction was for up to 1,575,784 shares, while Zhong Weifeng planned to reduce up to 302,158 shares. As of May 30, 2025, Jincheng Investment had reduced 1,575,708 shares and Zhong Weifeng had reduced 294,936 shares, with both deciding to terminate their reduction plans early [1][3].

Summary of Key Points Core Viewpoint - The announcement details the results of a share reduction plan by Zhejiang Gongdong Medical Instrument Co., Ltd, highlighting the amounts and percentages of shares sold by key stakeholders, including the early termination of the reduction plan [1][3]. Group 1: Shareholder Reduction Details - Taizhou Jinch Investment Management Partnership (Limited Partnership) planned to reduce its holdings by up to 1,575,784 shares, representing no more than 1% of the total share capital [1]. - The total shares reduced by Taizhou Jinch amounted to 1,575,708 shares, leaving it with 10,184,292 shares, which is 6.46% of the total share capital [1][3]. - Chairman and General Manager Zhong Weifeng planned to reduce his holdings by up to 302,158 shares, which is 0.19% of the total share capital, and he successfully reduced 294,936 shares, retaining 913,698 shares, or 0.58% of the total [1][3]. Group 2: Reduction Plan Implementation - The reduction period for Zhong Weifeng was from March 13, 2025, to May 30, 2025, with a total reduction amounting to 8,526,906.60 yuan at a price range of 28.08 to 30.98 yuan per share [2][3]. - Taizhou Jinch's reduction period was from March 11, 2025, to May 30, 2025, with a total reduction amounting to 43,171,696.32 yuan at a price range of 23.64 to 30.53 yuan per share [2][3]. - Both shareholders decided to terminate the reduction plan early, having met their planned reduction amounts [3].